Condition: Aging · Arterial Stiffness · Sponsor: University of Missouri-Columbia
Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.
This description comes directly from the study's public registry record.
Camila Manrique, MD · (573) 882-2554 · manriquec@health.missouri.edu
Andrea Atkins, BSN · (573) 884-1222 · wiesa@health.missouri.edu
Always discuss trial participation with your own doctor first.
| University of Missouri | Columbia, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06506422